The new human coronavirus named SARS-CoV-2 is a positive-sense RNA virus for which no specific drugs are currently available. A knowledge-based analysis strongly suggests a possible repositioning of the anti-HCV direct antiviral agent (DAA) Sofosbuvir as treatment for SARS-CoV-2. Indeed, the RNA-dependent RNA-polymerases (RdRp) of the two viruses show high sequence and structural homology, supporting the likelihood of binding the Sofosbuvir molecule with similar efficiency. Such a repositioning would allow the containment of the SARS-CoV-2 pandemic and limit the progression of disease to potentially deadly COVID19.
All Keywords
【초록키워드】 Treatment, SARS-CoV-2, coronavirus, COVID19, pandemic, Antiviral, drug, virus, sofosbuvir, RdRP, binding, Analysis, Efficiency, Anti-HCV, sequence, progression of disease, positive-sense RNA virus, structural homology, limit, likelihood, the SARS-CoV-2, 【제목키워드】 Antiviral, sofosbuvir, Anti-HCV, SARS-CoV-2 treatment,
【초록키워드】 Treatment, SARS-CoV-2, coronavirus, COVID19, pandemic, Antiviral, drug, virus, sofosbuvir, RdRP, binding, Analysis, Efficiency, Anti-HCV, sequence, progression of disease, positive-sense RNA virus, structural homology, limit, likelihood, the SARS-CoV-2, 【제목키워드】 Antiviral, sofosbuvir, Anti-HCV, SARS-CoV-2 treatment,